Friday 6 November 2026 Export HIMS’s income statement to Excel — free account

Hims & Hers Health, Inc.

HIMS Healthcare Drug Manufacturers Specialty & Generic

Hims & Hers Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 59.0% from fiscal 2024.

Revenue: +38.3%
EPS: −294.7%
Free cash flow: +5.09%
Total debt: +40.8%

Quarter to June 2026, against a year earlier

24.11 2.55 −9.56%

Follow HIMS

Alert me

Market cap: $5.6B
P/E: 0.0×
Fwd P/E: −49.4×
Dividend yield: —
F-score: 4/9
Altman Z: 4.10
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Hims & Hers Health, Inc. (HIMS) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by regions, and margins
UNITED STATES	2,214	94.29%
Non-US	134	5.71%
Gross margin		73.84%
Operating margin		4.50%
Pre-tax margin		5.28%

Revenue by region $m

Line	FY2025	FY2024	FY2023
UNITED STATES	2,214 94.29%	1,450 98.18%	854 97.99%
Non-US	134 5.71%	27 1.82%	18 2.01%
Revenue	2,348	1,477	872

Operating figures as reported in each quarter’s results release or filing

Figure	Quarter	Latest	A year before	Change
Monthly online revenue per average subscriber	Q4 FY2025	$82.00	$73.00	+12.33%
Monthly revenue per average subscriber	Q2 FY2026	$92.00	—	—
Subscribers	Q2 FY2026	2.9M	2.4M	+18.53%

	Q2 FY2026	Q1 FY2026	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024	Q3 FY2024	Q2 FY2024	Q1 FY2024	Q4 FY2023	Q3 FY2023
Monthly online revenue per average subscriber	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Monthly revenue per average subscriber	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Subscribers	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.